A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.

@article{Albain1995API,
  title={A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904.},
  author={Kathy S. Albain and P. Y. Liu and Alexander Hantel and Elizabeth A. Poplin and Robert V. O’Toole and James L. Wade and Anne Marie Maddox and David S. Alberts},
  journal={Gynecologic oncology},
  year={1995},
  volume={57 3},
  pages={
          407-11
        }
}
A phase II trial of the new anthrapyrazole piroxantrone was conducted by the Southwest Oncology Group in advanced ovarian carcinoma. The objective were to evaluate its response rate and toxicity in patients who had disease persistence, progression, or recurrence either during or after platinum-containing chemotherapy. A two-stage statistical design targeted accrual to 15 eligible patients if no responses were observed. The piroxantrone starting dose was 120 mg/m2, with the provision to escalate… 
4 Citations
Synthetic DNA-Targeted Chemotherapeutic Agents And Related Tumor-Activated Prodrugs
TLDR
Using hypoxia, gene therapy or antibody targeting to activate such prodrugs specifically in tumor tissue has the potential to increase the therapeutic index of these agents by limiting the exposure of sensitive nontumor cell populations.
Structure-activity studies with cytotoxic anthrapyrazoles.
TLDR
A structure-activity study was carried out to determine the in vitro cytotoxic activity of nine novel anthrapyrazole analogues against human breast carcinoma, head and neck squamous cell carcinoma and leukemia cells, and against Chinese hamster ovary cells.
Epithelial ovarian cancer: Prevention, diagnosis, and treatment
The leading cause of death from gynecologic malignancies in the United States is epithelial ovarian cancer. The significant risk factor for development of ovarian cancer is advancing age, although